A double-blind, placebo-controlled trial of i.v. dolasetron mesilate in the prevention of radiotherapy-induced nausea and vomiting in cancer patients

Supportive Care in Cancer

Volumn 4, Issue 5, 1996, Pages 378-383

  Bey, P ^a   Wilkinson, P M ^b   Resbeut, M ^c   Bourdin, S ^d   Le Floch, O ^e   Hahne, W ^f   Claverie, N ^f  

^a CENTRE ALEXIS VAUTRIN   (France)

^b CHRISTIE HOSPITAL   (United Kingdom)

^c INSTITUT PAOLI CALMETTES   (France)

^d CENTRE RENÉ GAUDUCHEAU   (France)

^e UNIVERSITY HOSPITAL OF TOURS   (France)

^f SANOFI   (France)

Author keywords

5 HT3 receptor antagonists; Dolasetron mesilate; Emesis high dose radiotherapy

Indexed keywords

ANTIEMETIC AGENT; DOLASETRON MESILATE; INDOLE DERIVATIVE; QUINOLIZINE DERIVATIVE;

ADULT; AGED; ANALYSIS OF VARIANCE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; MEGAVOLTAGE RADIOTHERAPY; MIDDLE AGED; NAUSEA; NEOPLASM; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL; STATISTICAL MODEL; TREATMENT OUTCOME; VOMITING;

ADULT; AGED; ANALYSIS OF VARIANCE; ANTIEMETICS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INDOLES; INJECTIONS, INTRAVENOUS; LINEAR MODELS; MALE; MIDDLE AGED; NAUSEA; NEOPLASMS; QUINOLIZINES; RADIOTHERAPY, HIGH-ENERGY; TREATMENT OUTCOME; VOMITING;

EID: 0030227570     PISSN: 09414355     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01788845     Document Type: Article

References (17)

1. Andrews PLR, Howthorn J, Sanger GJ (1986) The effect of abdominal visceral nerve lesions and a novel 5-HT-M receptor antagonist on cytotoxic and radiation-induced emesis in the ferret. J Physiol 382:47P
2. Audhuy B, Cappelaeare P, Claverie N (1995) Double-blind comparative trial of the antiemetic efficacy of two i.v. doses of dolasetron mesilate (DM) and granisetron (G) after infusion with high-dose cisplatin chemotherapy (abstract). Eur J Cancer 31A [Suppl 5]:S253
3. Bigaud M, Elands J, Kastner PR, Bohnke RA, Emmert LW, Galvan M (1995) Pharmacology of the human metabolites of dolasetron, an antiemetic 5-HT3 receptor antagonist. Drug Dev Res 34:289-296
4. Chevallier B, Cappelaere P, Splinter T, Fabbro M, Wendling JL, Cals L, Clavel M, Giovannini M, Khayat D, Claverie N, Hahne W (1995) IV Dolasetron (DM) vs IV metoclopramide (M) in emesis prevention after cisplatin chemotherapy (CT) (abstract). Support Care Cancer 3:336
5. Conroy T, Cappelaere P, Fabbro M, et al (1994) Acute antiemetic efficacy and safety of dolasetron mesilate, a 5-HT3 antagonist, in cancer patients treated with cisplatin. J Clin Oncol 17:97-102
6. Court-Brown WM (1953) Symptomatic disturbance of the single therapeutic dose of X-rays. Br Med J 1:802-804
7. Danjoux CE, Rider WD, Fitzpatrick PJ (1979) The acute radiation syndrome. A memorial to William Michael Court-Brown. Clin Radiol 30:581-584
8. Harman G, Omura G, Ryan K, et al (1996) A randomized, double-blind comparison of single-dose and divided multiple-dose dolasetron for cisplatin-induced emesis. Cancer Chemother Pharmacol (in press)
9. Kris MG, Grunberg SM, Gralla RJ, et al (1994) Dose-ranging evaluation of the serotonin antagonist dolasetron mesilate in patients receiving high-dose cisplatin. J Clin Oncol 12:1045-1049
10. Miller RC, Galvan M, Gittos MW, Giersbergen PLM van, Moser PC, Fozard JR (1993) Pharmacological properties of dolasetron, a potent and selective antagonist at 5-HT3 receptors. Drug Dev Res 28:87-93
11. Plezia P, Modiano M, Alberts D, et al (1992) A double-blind, randomized, parallel study of two doses of intravenous (IV) MDL 73,147EF in patients (PTS) receiving high dose cisplatin (CPPD)-containing chemotherapy (abstract). Proc Am Soc Clin Oncol 11:407
12. Priestman TJ (1989) Clinical studies with ondansetron in the control of radiation induced emesis. Eur J Cancer Clin Oncol 25 [Suppl 1]:S29-S33
13. Priestman TJ, Priestman SG (1992) Clinical trials in the prevention and control of emesis induced by therapeutic radiation. Colloque Inserm 223:157-165
14. Priestman TJ, Roberts JT, Lucraft H, et al (1990) Results of a randomized double-blind, comparative study of ondansetron and metoclopramide in the prevention of nausea and vomiting following high-dose upper abdominal irradiation. J Clin Oncol 2:71-75
15. Salazar OM, Rubin P, Keller B, Scarantino C (1978) Systemic (half-body) radiation therapy: response and toxicity. Int J Radiat Oncol Biol Phys 4:937-950
16. Sorbe B, Berglind AM (1992) Tropisetron, a new 5-HT3 receptor antagonist in the prevention of radiation-induced nausea, vomiting, and diarrhoea. Drugs 43 [Suppl 2]:33-39
17. Young RW (1992) Mechanisms and treatment of radiation-induced nausea and vomitina. Colloque Inserm 223:157-165